# PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma

> **NCT00049530** · PHASE2 · COMPLETED · sponsor: **Eastern Cooperative Oncology Group** · enrollment: 32 (actual)

## Conditions studied

- Melanoma (Skin)

## Interventions

- **BIOLOGICAL:** PEG-interferon alfa-2b

## Key facts

- **NCT ID:** NCT00049530
- **Lead sponsor:** Eastern Cooperative Oncology Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-01-13
- **Primary completion:** 2012-08
- **Final completion:** 2014-06
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2023-06-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00049530

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00049530, "PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00049530. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*